Literature DB >> 9187391

Determination of imipenem in plasma by high-performance liquid chromatography for pharmacokinetic studies in patients.

L Garcia-Capdevila1, C López-Calull, C Arroyo, M A Moral, M A Mangues, J Bonal.   

Abstract

A rapid and simple HPLC method is described for the determination of imipenem in human plasma. After blood collection, plasma was separated by centrifugation and immediately stabilized with 3-morpholinopropanesulfonic acid (MOPS) and ethylene glycol solution (1:1). The sample preparation, before injection into HPLC, was ultrafiltration. The mobile phase was boric acid buffer. The imipenem was detected at 300 nm and cilastatin sodium, coadministered, did not interfere. Calibration curves in human plasma were linear from 0.1 to 100 microg/ml. The limit of detection was 0.030 microg/ml. Inter-day precision at 0.1 microg/ml, determined as the coefficient of variation, was 6.26%. Only 250 microl of plasma was required in our assay. Due to the limited stability of imipenem [G.B. Smith et al., J. Pharm. Sci., 79 (1990) 732], stability studies in plasma were done to establish appropriate storage conditions. The assay was applied to pharmacokinetic studies in patients.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9187391     DOI: 10.1016/s0378-4347(96)00498-7

Source DB:  PubMed          Journal:  J Chromatogr B Biomed Sci Appl        ISSN: 1387-2273


  8 in total

1.  Population pharmacokinetics of arbekacin, vancomycin, and panipenem in neonates.

Authors:  Toshimi Kimura; Keisuke Sunakawa; Nobuo Matsuura; Hiroaki Kubo; Shigehiko Shimada; Kazuo Yago
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

2.  Prospective determination of plasma imipenem concentrations in critically ill children.

Authors:  Eric Giannoni; Philippe Moreillon; Jacques Cotting; Adrien Moessinger; Jacques Bille; Laurent Décosterd; Giorgio Zanetti; Paul Majcherczyk; Denis Bugnon
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

3.  Cefoxitin as an alternative to carbapenems in a murine model of urinary tract infection due to Escherichia coli harboring CTX-M-15-type extended-spectrum β-lactamase.

Authors:  Raphaël Lepeule; Etienne Ruppé; Patrick Le; Laurent Massias; Françoise Chau; Amandine Nucci; Agnès Lefort; Bruno Fantin
Journal:  Antimicrob Agents Chemother       Date:  2012-01-03       Impact factor: 5.191

4.  Analysis of Paradoxical Efficacy of Carbapenems against Carbapenemase-Producing Escherichia coli in a Murine Model of Lethal Peritonitis.

Authors:  Ariane Roujansky; Victoire de Lastours; François Guérin; Françoise Chau; Geoffrey Cheminet; Laurent Massias; Vincent Cattoir; Bruno Fantin
Journal:  Antimicrob Agents Chemother       Date:  2020-07-22       Impact factor: 5.191

5.  Population pharmacokinetics of imipenem in critically ill patients with suspected ventilator-associated pneumonia and evaluation of dosage regimens.

Authors:  Camille Couffignal; Olivier Pajot; Cédric Laouénan; Charles Burdet; Arnaud Foucrier; Michel Wolff; Laurence Armand-Lefevre; France Mentré; Laurent Massias
Journal:  Br J Clin Pharmacol       Date:  2014-11       Impact factor: 4.335

6.  Comparative stability studies of antipseudomonal beta-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units).

Authors:  Eric Viaene; Hugues Chanteux; Hélène Servais; Marie-Paule Mingeot-Leclercq; Paul M Tulkens
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

7.  Nonvolatile salt-free stabilizer for the quantification of polar imipenem and cilastatin in human plasma using hydrophilic interaction chromatography/quadrupole mass spectrometry with contamination sensitive off-axis electrospray.

Authors:  Zhe-Yi Hu; Bradley A Boucher; S Casey Laizure; Vanessa L Herring; Robert B Parker; William L Hickerson
Journal:  J Mass Spectrom       Date:  2013-08       Impact factor: 1.982

8.  Pharmacokinetics and Monte Carlo Dosing Simulations of Imipenem in Critically Ill Patients with Life-Threatening Severe Infections During Support with Extracorporeal Membrane Oxygenation.

Authors:  Sutep Jaruratanasirikul; Veerapong Vattanavanit; Wibul Wongpoowarak; Monchana Nawakitrangsan; Maseetoh Samaeng
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2020-12       Impact factor: 2.441

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.